Search research articles
Contact Us
Filters
Showing results (21-30 of 66) with videos related to
Page
of 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2019
Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2)
Rathi N Pillai, Dean A Fennell, Vladimir Kovcin, et al.
Journal of Clinical Medicine
|
August 28, 2025
Risk Stratification Using a Perioperative Nomogram for Predicting the Mortality of Bladder Cancer Patients Undergoing Radical Cystectomy
Daniel-Vasile Dulf, Anamaria Larisa Burnar, Patricia-Lorena Dulf, et al.
International Journal of Environmental Research and Public Health
|
April 12, 2022
Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients
Radu Vidra, Tudor Eliade Ciuleanu, Adina Nemeș, et al.
Frontiers in Immunology
|
October 6, 2025
The miRNA-immune axis in bladder cancer: systematic evidence for a new era of immunotherapy precision
Daniel-Vasile Dulf, Gloria Ravegnini, Federico Manuel Giorgi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2012
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial
Rodryg Ramlau, Vera Gorbunova, Tudor Eliade Ciuleanu, et al.
Journal of Clinical Medicine
|
July 29, 2025
Lymphovascular Invasion Is a Predictor of Clinical Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy
Daniel-Vasile Dulf, Anamaria Larisa Burnar, Patricia-Lorena Dulf, et al.
Medicine and Pharmacy Reports
|
May 21, 2026
Real-world benchmarks for metastatic urothelial carcinoma: a single-center analysis of two standard immunotherapy pathways in Romania
Daniel-Vasile Dulf, Anamaria Larisa Burnar, Doina-Ramona Matei, et al.
Cancers
|
June 19, 2024
Use of Different Anti-PD-1 Checkpoint Combination Strategies for First-Line Advanced NSCLC Treatment-The Experience of Ion Chiricuță Oncology Institute
Alexandra-Cristina Preda, Tudor-Eliade Ciuleanu, Nicolae Todor, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 2, 2017
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer
Luis G Paz-Ares, Maurice Pérol, Tudor-Eliade Ciuleanu, et al.
Journal of Cellular and Molecular Medicine
|
June 16, 2021
Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy
Sabina Iluta, Sergiu Pasca, Grigore Gafencu, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 66) with videos related to
Sort By:
Page
of 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2019
Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2)
Rathi N Pillai, Dean A Fennell, Vladimir Kovcin, et al.
Journal of Clinical Medicine
|
August 28, 2025
Risk Stratification Using a Perioperative Nomogram for Predicting the Mortality of Bladder Cancer Patients Undergoing Radical Cystectomy
Daniel-Vasile Dulf, Anamaria Larisa Burnar, Patricia-Lorena Dulf, et al.
International Journal of Environmental Research and Public Health
|
April 12, 2022
Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients
Radu Vidra, Tudor Eliade Ciuleanu, Adina Nemeș, et al.
Frontiers in Immunology
|
October 6, 2025
The miRNA-immune axis in bladder cancer: systematic evidence for a new era of immunotherapy precision
Daniel-Vasile Dulf, Gloria Ravegnini, Federico Manuel Giorgi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2012
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial
Rodryg Ramlau, Vera Gorbunova, Tudor Eliade Ciuleanu, et al.
Journal of Clinical Medicine
|
July 29, 2025
Lymphovascular Invasion Is a Predictor of Clinical Outcomes in Bladder Cancer Patients Treated with Radical Cystectomy
Daniel-Vasile Dulf, Anamaria Larisa Burnar, Patricia-Lorena Dulf, et al.
Medicine and Pharmacy Reports
|
May 21, 2026
Real-world benchmarks for metastatic urothelial carcinoma: a single-center analysis of two standard immunotherapy pathways in Romania
Daniel-Vasile Dulf, Anamaria Larisa Burnar, Doina-Ramona Matei, et al.
Cancers
|
June 19, 2024
Use of Different Anti-PD-1 Checkpoint Combination Strategies for First-Line Advanced NSCLC Treatment-The Experience of Ion Chiricuță Oncology Institute
Alexandra-Cristina Preda, Tudor-Eliade Ciuleanu, Nicolae Todor, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 2, 2017
Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer
Luis G Paz-Ares, Maurice Pérol, Tudor-Eliade Ciuleanu, et al.
Journal of Cellular and Molecular Medicine
|
June 16, 2021
Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy
Sabina Iluta, Sergiu Pasca, Grigore Gafencu, et al.
Page
of 7